Condition (MeSH)
Gigantism
ClinicalTrials.gov lists 8 trials for Gigantism or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
8 of the 8 trials are tagged with Gigantism itself; the rest are tagged with a narrower condition beneath it.
When did Gigantism trials start? (8)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 1
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2019 | 1 |
| 2015 | 1 |
| 2014 | 1 |
| 2013 | 1 |
| 2012 | 1 |
| 2007 | 1 |
| 1997 | 1 |
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Gigantism trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 3 |
| Phase 4 | 1 |
| Not applicable | 1 |
| Observational | 2 |
How many Gigantism trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 3 |
| Completed | 3 |
| Terminated | 1 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Gigantism trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 2 |
| Novartis Pharmaceuticals | 2 |
| Debiopharm International SA | 1 |
Which serious adverse events do Gigantism trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Hyperglycaemia | 5 | 2 |
| Adrenal insufficiency | 4 | 1 |
| Bile duct stone | 4 | 2 |
| Inguinal hernia | 4 | 1 |
| Large intestine polyp | 4 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Gigantism? (7)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Increased Population Risk of AIP-Related Acromegaly and Gigantism in Ireland. | Human mutation | 2017 | Yes |
| Pituitary gigantism: update on molecular biology and management. | Current opinion in endocrinology, diabetes, and obesity | 2016 | Yes |
| Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study. | Acta neuropathologica communications | 2016 | Yes |
| Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. | The New England journal of medicine | 2014 | Yes |
| AIP mutation in pituitary adenomas in the 18th century and today. | The New England journal of medicine | 2011 | Yes |
Showing 5 of 7 publications.
Prevalence (3)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Pituitary gigantism | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Pituitary gigantism | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
| Pituitary gigantism | Point prevalence | Unknown | Worldwide | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Pituitary gigantism | 99725 | Exact | Orphadata Science knowledge files, Product 1 |
| Pituitary gigantism | 99725 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.